ApprovedFDA approval

Veppanu (vepdegestrant)

Rigel Pharmaceuticals (RIGL)

Marketer take

An oral ER degrader for ESR1-mutated breast cancer after endocrine therapy, competing with Orserdu and AstraZeneca's Etcamah, so ESR1 testing and oncologist sequencing decisions are the battleground.

Sponsor company
Rigel Pharmaceuticals (RIGL)
Indication
To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
Therapeutic area
Oncology
Event
FDA approval
Date
May 1, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move